Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Revenue (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Revenue for 16 consecutive years, with $57.2 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 7.58% to $57.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $216.1 million through Dec 2025, up 8.72% year-over-year, with the annual reading at $216.1 million for FY2025, 8.72% up from the prior year.
  • Revenue hit $57.2 million in Q4 2025 for Vanda Pharmaceuticals, up from $56.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $70.1 million in Q3 2021 to a low of $38.8 million in Q3 2023.
  • Historically, Revenue has averaged $56.5 million across 5 years, with a median of $56.7 million in 2025.
  • Biggest five-year swings in Revenue: crashed 40.58% in 2023 and later grew 22.76% in 2024.
  • Year by year, Revenue stood at $68.0 million in 2021, then dropped by 5.2% to $64.5 million in 2022, then decreased by 29.79% to $45.3 million in 2023, then rose by 17.48% to $53.2 million in 2024, then rose by 7.58% to $57.2 million in 2025.
  • Business Quant data shows Revenue for VNDA at $57.2 million in Q4 2025, $56.3 million in Q3 2025, and $52.6 million in Q2 2025.